Media Outlets Highlight New Research from Dr. Steven Houser and Lewis Katz School of Medicine Team Showing Already-Approved Medication Could Treat Common Form of Heart Failure

Steven R. Houser, PhD, FAHA, Senior Associate Dean of Research, Vera J. Goodfriend Endowed Chair of Cardiovascular Research, Chair and Professor of Physiology and Professor of Medicine, and Director of the Cardiovascular Research Center at the Lewis Katz School of Medicine at Temple University (LKSOM), was the senior investigator on a new study published in the journal Science Translational Medicine. Dr. Houser and a team of scientists from LKSOM and the University of Colorado investigated the effects of a histone deacetylase inhibitor known as SAHA (Zolinza) on animals with a common form of heart failure known as heart failure with preserved ejection fraction (HFpEF). Zolinza is already approved for the treatment of certain forms of cancer and showed in the study that it can reverse HFpEF symptoms and improve the heart’s ability to pump blood in an HFpEF animal model. Scienmag, Bioengineer.org, News-Medical.net, Medical Xpress, Cardiovascular Business, and additional media outlets highlighted the research.